NCT01561768已完成2 期
A Phase 2 Randomized, Observer-Blind, Dose-Ranging Study to Evaluate the Immunogenicity and Safety of Quadrivalent Seasonal Virus-Like Particle (VLP) Influenza Vaccine (Recombinant) in Healthy Young (18-64) Adults
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- Novavax
- 入组人数
- 500
- 试验地点
- 4
- 主要终点
- Immunogenicity of 3 dose levels of the Novavax Quadrivalent vaccine based on HAI responses
研究概览
简要总结
The purpose of this study is to determine the immune response of three dose levels of the Novavax Quadrivalent vaccine in healthy young adults (18-64). The study is broken down into 5 treatment groups. Each group will enroll 100 subjects, for a total of 500 subjects. Group 1-3 will receive one of three dose levels of the Novavax Quadrivalent vaccine, Group 4 will receive a dose of the Novavax Trivalent vaccine, and Group 5 will receive a commercially available trivalent influenza vaccine (TIV). The study will also evaluate the safety and tolerability of the Novavax Quadrivalent vaccine.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Triple (Participant, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 64 Years（Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Healthy adult male or females, 18-64 years of age
- •Willing and able to give informed consent prior to study enrollment
- •Able to comply with study requirements
- •Women who are not post-menopausal (≥ 50 years of age and at least one year post last menses) or surgically sterile must have a negative urine pregnancy test at vaccination; will be advised through the Informed Consent process to avoid becoming pregnant over the duration of the study, and must assert that they will employ an effective form of birth control for the duration of the study. Acceptable forms of birth control are: credible history of abstinence from heterosexual activity, hormonal contraceptives (oral, injectable, implant, patch, ring), double-barrier contraceptives (condom or diaphragm, with spermicide), and intrauterine device (IUD)
排除标准
- •Participation in research involving investigational product (drug/biologic/device) within 45 days before planned date of first vaccination
- •History of a serious reaction to prior influenza vaccination, known allergy to constituents of licensed TIV (e.g., egg proteins) or polysorbate-80
- •History of Guillain-Barré Syndrome (GBS) within 6 weeks following a previous influenza vaccine
- •Received any vaccine in the 4 weeks preceding the study vaccination and any influenza vaccine within six months preceding the study vaccination
- •Any know or suspected immunosuppressive illness, congenital or acquired, based on medical history and/or physical examination
- •Chronic administration (defined as more than 14 continuous days) of immunosuppressants or other immune-modifying drugs within 6 months prior to the administration of the study vaccine. An immunosuppressant dose of glucocorticoid will be defined as a systemic dose ≥10 mg of prednisone per day or equivalent. The use of topical, inhaled, and nasal glucocorticoids will be permitted.
- •Administration of immunoglobulins and/or any blood products within the 3 months preceding the administration of the study vaccine or during the study
- •Acute disease at the time of enrollment (defined as the presence of a moderate or severe illness with or without fever, or an oral temperature >38.0°C on the planned day of vaccine administration)
- •Presence of chronic pulmonary (including asthma), cardiovascular (except hypertension), renal, hepatic, neurologic, hematologic or metabolic (including diabetes mellitus) disorders, which would include the potential subject in a "high-risk" category for influenza and/or its complications
- •Known disturbance of coagulation
- •Women who are breastfeeding or plan to become pregnant during the study
- •Suspicion or recent history (within one year of planned vaccination) of alcohol or other substance abuse
- •Any condition that in the opinion of the investigator would pose a health risk to the subject if enrolled or could interfere with evaluation of the vaccine or interpretation of study results (including neurologic or psychiatric conditions deemed likely to impair the quality of safety reporting)
结局指标
主要结局
Immunogenicity of 3 dose levels of the Novavax Quadrivalent vaccine based on HAI responses
时间窗: Day 21
Number of Solicited and Unsolicited Adverse Events for the Novavax Quadrivalent vaccine
时间窗: 6 months
次要结局
- Estimate capacity of the Novavax Quadrivalent vaccines to fulfill FDA criteria (immunogenicity) for all strains in healthy, young adults(Day 21)
- Impact of including a fourth strain in the Novavax Quadrivalent vaccine on immune responses to other three strains(Day 21)
研究者
研究点 (4)
Loading locations...
相似试验
已完成
2 期
Quadrivalent Influenza VLP Vaccine Dose Ranging Study in Young AdultsInfluenzaNCT02307851Novavax400
已完成
3 期
Phase 3 Study of Novavax Vaccine(s) as Booster Dose After mRNA VaccinesCOVID-19NCT05875701Novavax147
已完成
2 期
Safety and Immunogenicity of Two Adjuvanted and One Non-adjuvanted H5N1 Influenza Vaccine in AdultsInfluenzaNCT00382187Novartis Vaccines40
已完成
2 期
Safety and Immunogenicity of Two Doses, Administered Three Weeks Apart, of Two(Surface Antigen Adjuvanted With MF59C.1) Influenza Vaccines in Non-Elderly Adult and Elderly SubjectsPandemic Influenza DiseaseNCT00311480Novartis520
已完成
2 期
Safety, Tolerability and Immunogenicity of Three Doses of Novartis Meningococcal B Vaccine When Administered to Healthy At-risk AdultsMeningococcal DiseaseNCT00560313Novartis Vaccines54